Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors

SEATTLE, March 3, 2015 /PRNewswire/ -- Adaptive Biotechnologies announced today that Chad Cohen, Zillow Group CFO, is joining its Board of Director as Chair of the Audit Committee.

As chief financial officer at Zillow Group, Chad oversees all finance, treasury and accounting functions. Since joining Zillow in 2006, Chad built the company's core finance, treasury and accounting functions, and led the finance organization through Zillow's 2011 IPO and nine acquisitions. In 2013, he was named Puget Sound Business Journal's CFO of the year. Before joining Zillow, Chad worked for Ticketmaster Entertainment as assistant controller and financial integrity manager. Previously, Chad was vice president and assistant controller for Countrywide Bank and supervising senior auditor at Ernst & Young. He started his career as a financial planning analyst for Novellus Systems. Chad also serves as an independent director for Ticketfly, a progressive live-event and consumer ticketing company located in San Francisco.

"We are delighted to have Chad Cohen join the Board,"said Chad Robins, CEO and Founder of Adaptive Biotechnologies. "Mr. Cohen has a unique set of experiences evolving the financial organization and infrastructure for disruptive technologies as they mature. This skillset will be extremely valuable to Adaptive."

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages NGS to profile T-Cell and B-Cell Receptors. This breakthrough enables in-depth characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis and monitoring of cancer patients.

About immunoSEQTM

Adaptive helps researchers make discoveries in oncology, autoimmune disorders and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology under the immunoSEQTM brand name. The immunoSEQTM Kit for research use only is now available to facilitate the integration of immunosequencing into research centers. The immunoSEQ Assay is not for use in diagnostic procedures.

About clonoSEQTM

Adaptive uses its proprietary immunosequencing platform to validate clinical diagnostics in cancer and other immune-mediated diseases. The company's first CLIA certified clinical application, the clonoSEQTM Assay, is used to monitor Minimal Residual Disease (MRD) in blood-based cancers. Improving the ability to accurately detect and track residual disease at a molecular level affords clinicians the potential to detect relapse earlier and improve patient care.

The company is currently validating a second novel oncology diagnostic to quantify the presence and clonality of Tumor Infiltrating Lymphocytes ("TILs") and to create a reliable measure of "immunocompetency" to predict or monitor response to cancer treatments that directly alter the host immune system.

Logo - http://photos.prnewswire.com/prnh/20120103/SF28632LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/adaptive-biotechnologies-adds-chad-cohen-zillow-group-cfo-to-board-of-directors-300044576.html

SOURCE Adaptive Biotechnologies Corporation

[ Back To TMCnet.com's Homepage ]